devinitorg/iati-policy-markers huggingface dataset:
Feasibility Study - Rwanda: Kigali Innovation Smart City, through Enterprise - United States Unknown A USTDA grant to the Rwanda Development Board is funding a feasibility study (Study) that would assess (i) various options for deployment of smart city solutions at Kigali Innovation City, a planned mixed-use development intended to serve as a hub for the technology industry in Kigali, and (ii) the feasibility of further deployments of smart city technologies throughout Rwanda.
Technical Assistance - Banque Nationale du Rwanda ICT Modernization, through U.S. Government - Trade and Development Agency Technical Assistance - Banque Nationale du Rwanda ICT Modernization, through U.S. Government - Trade and Development Agency
Feasibility Study - COMMUNICATION INFRASTRUCTURE BACKBONE, through Government of Rwanda Feasibility Study - COMMUNICATION INFRASTRUCTURE BACKBONE, through Government of Rwanda
Technical Assistance - Rwaza I & II Hydropower Projects, through Ritoch-Powell & Associates Consulting Engineers, Inc. Rwaza I & II Hydropower Projects Technical Assistance
Desk Study - U.S.-ACEF Amahoro Energy Small Hydro Projects, through CJ Aron Associates, Inc. This $5,000 desk study reviewed a proposal for a feasibility study to evaluate the technical, financial, and other aspects of four small hydro expansion, rehabilitation, and development projects in Musanze District, Northern Province, Rwanda.
Technical Assistance - BANQUE NATIONALE DU RWANDA ICT MODERNIZATION, through Government of Rwanda This $547,000 grant to Rwanda's National Bank, Banque Nationale Du Rwanda (BNR) for a technical assistance (TA) assists BNR in building the technical capabilities to provide real-time cash balance information to policymakers. These capabilities will build capacity for more effective fiscal policy formulation and budget execution at the Ministry of Finance. Specifically, this activity will improve the Government of Rwanda's cash management and reduce unnecessary borrowing, enable more accurate cash forecasting and budget implementation, tighten financial control of ongoing long term projects, and provide greater transparency and less opportunity for misuse of funds.
Desk Study - Desk Study Review: Banque Nationale Du Rwnada ICT Modernization, through Global Resources, Inc. This $6,000 desk study reviews a proposal for an addendum to the Banque National du Rwanda (BNR) ICT Modernization Technical Assistance (USTDA 2010-11009A). The addendum would provide BNR with assistance in evaluating proposals for its core banking and enterprise resource planning RFP's, as well as assistance with contract negotiations.
Desk Study - Banque National du Rwanda ICT Modernization DSR, through U.S. Government - Trade and Development Agency This desk study review reviews a proposed deliverable in the TOR of the Banque Nationale du Rwanda ICT Modernization Technical Assistance.
Desk Study - DE MINIMIS TRAINING, CIVIL AVIATION SECTOR MODERNIZATION, through KED Group, LLC This $12,500 Desk Study develops a terms of reference and budget for the de minimis training, Civil Aviation Sector Modernaization (USTDA Activity # 2012-11009) for Rwanda.
Feasibility Study - U.S.-ACEF Amahoro Energy Small Hydro Projects, through Government of Rwanda A USTDA grant of $675,000 to the Rwandan energy developer Amahoro Energy Ltd. is supporting a feasibility study to evaluate the company's plans to develop a greenfield run-of-river hydropower plant and upgrade expansion of five existing small hydropower sites located in Rwanda's northeast Musanze District (Project). The Project would be developed in two phases over a two-year period and would install a combined 11.45 megawatts (MW) of new generation capacity. If implemented, the Project would directly support Rwanda's Economic Development and Poverty Reduction Strategy and national Energy Sector Strategic Plan by increasing renewable energy generation and helping to electrify over 22,500 households, businesses, and the Shiyira Hospital. The feasibility study is being undertaken on a sole-source basis by the U.S. engineering firm Knight Piesold & Co. (Contractor). The Grantee has agreed to share costs of the total feasibility study cost of $800,000.
Technical Assistance - Banque Nationale du Rwanda ICT Modernization, through Government of Rwanda This $547,000 grant to Rwanda's National Bank, Banque Nationale Du Rwanda (BNR), for technical assistance (TA) assisted BNR in building the technical capabilities to provide real-time cash balance information to policymakers. These capabilities will build capacity for more effective fiscal policy formulation and budget execution at the Ministry of Finance. Specifically, this activity will improve the Government of Rwanda's cash management and reduce unnecessary borrowing, enable more accurate cash forecasting and budget implementation, tighten financial control of ongoing long-term projects, and provide greater transparency and less opportunity for misuse of funds.
Feasibility Study - U.S.-ACEF Amahoro Energy Small Hydro Projects, through Knight Piesold US-ACEF Amahoro Energy Small Hydro Projects Feasibility Study
Desk Study - BANQUE NATIONALE DU RWANDA ICT MODERNIZATION, through U.S. Government - Trade and Development Agency This $5,000 desk study reviews a proposal for modification to the Banque Nationale du Rwanda (BNR) ICT Modernization Technical Assistance (USTDA No. 201011009) Terms of Reference.
Technical Assistance - Banque Nationale du Rwanda ICT Modernization, through Government of Rwanda Technical Assistance - Banque Nationale du Rwanda ICT Modernization, through Government of Rwanda
DNDi General Management Established in 2003 in Geneva, Switzerland, DNDi’s headquarters is active in Research & Development activities, as well as in administrative and support functions, including Finance, Human Resources, IT, Policy, Advocacy, Communications and External Relations. Teams manage projects and partnerships so that new and adapted treatments are developed for neglected patients and people with neglected tropical diseases such as sleeping sickness, leishmaniasis, Chagas disease, paediatric HIV, filarial diseases, mycetoma, hepatitis C, and others. From 2016 until 2018, DNDi Geneva incubated the WHO-DNDi joint initiative Global Antibiotic Research & Development Partnership (GARDP), a not-for-profit research and development organization developing and delivering new or improved antibiotic treatments, functioning as an independent entity since July 2018.
Paediatric HIV and cryptococcal meningitis Until recently, antiretroviral treatment for children was complex and difficult for caregivers to administer – including syrups that required refrigeration and tasted bitter. Together with our partners, we developed an easy-to-administer fixed-dose formulation of four drugs recommended for children with HIV. The ‘4-in-1’ combination treatment comes in strawberry-flavoured granules that are palatable and can easily be sprinkled on water, milk, or food, radically simplifying treatment administration for mothers and caregivers. 1. Make sure optimal antiretroviral treatment is available to all children who need it, while ensuring access to safe, affordable, well-adapted, and effective treatment for cryptococcal meningitis. 2. Explore how we can work with partners to unblock market failures and address gaps in pharmaceutical R&D to ensure all people living with HIV have access to the right treatment at the right time, wherever they live.
Open Innovation  Booster and Lead Optimization consortium DNDi’s open and collaborative approach to R&D – driven by patient needs, not profits – serves as a practical illustration of how alternatives to the prevailing system of commercial R&D can be organized and implemented, and how they can deliver for people in need.
To speed up early-stage research and reduce overall R&D costs, DNDi works to enable research actors to actively collaborate without the restraints of intellectual property, supporting and coordinating a number of open innovation collaborations, including the NTD Drug Development Booster, Mycetoma Open Source project (MycetOS), and Open Synthesis Network (OSN). Open and collaborative drug discovery at DNDi continues to grow and expand, ranging from work with university chemistry teaching labs to support drug discovery, through to a virtual Open Pharma community to support lead optimization of chemical compounds that could one day become new medicines.
Leishmaniasis With its partners, DNDi has developed four improved Visceral Leishmaniasis (VL) treatments, including two in 2022 alone. 
 
1. Before 2010, the treatments available for visceral leishmaniasis in Africa had serious limitations: liposomal amphotericin B was very costly, and antimonials such as sodium stibogluconate were difficult to administer – with long treatment times and frequent side effects – and had emerging resistance. DNDi conducted clinical trials showing that the combination of sodium stibogluconate and paramomycin (SSG&PM) was as safe and effective as the existing standard treatment. With SSG&PM, treatment now lasts 17 days instead of 30 days, and costs less. The shorter treatment is easier on patients and health centres, and more people can be treated during outbreaks. It has been recommended by WHO as first-line treatment for visceral leishmaniasis in East Africa since 2010. DNDi continues to support the implementation of this treatment in East Africa.

2. In 2010, WHO recommended using new short-course treatments for visceral leishmaniasis in South Asia based on excellent results in DNDi Phase III studies. However, more evidence was needed on the safety and effectiveness of using these treatments for in wider populations under field conditions. In 2013, based on the interim safety data from a trial conducted by DNDi, Brazil’s national guidelines for visceral leishmaniasis were revised to include treatment with liposomal amphotericin B for some patients. 

3. In June 2022, the Pan American Health Organization (PAHO) published new guidelines for the treatment of leishmaniasis in the Americas recommending liposomal amphotericin B for the treatment of visceral leishmaniasis instead of pentavalent antimonials.

4. In June 2022, based on the results of two studies conducted since 2014 in Ethiopia and India (led by MSF), the World Health Organization released new treatment guidelines for the treatment of people co-infected with visceral leishmaniasis and HIV, recommending a combination of liposomal amphotericin B with miltefosine. 

Additionally, DNDi has replenished the R&D pipeline with an unprecedent portfolio of all-new potential drugs that could revolutionize treatment and accelerate progress towards global elimination goals. DNDi goal is to ensure access to safer, shorter treatments with existing drugs in the near term. Over the longer term, DNDi aims to develop all-new treatments with new chemical entities that are safe, effective, and easier to manage at the primary healthcare level, with the aim of bringing prompt diagnosis and treatment closer to patients.
Human african trypanosomiasis (HAT) / sleeping sickness DNDi has been focused on developing better treatments for sleeping sickness 
since its inception in 2003. By 2009, working closely with partners, DNDi finalized the development of nifurtimox and eflornithine (NECT), a simpler, safer treatment for the second stage of the most common form of the disease. In 2018, DNDi and its partners delivered fexinidazole, a paradigm-changing simple oral treatment for both stages of the disease that can be taken at home. The clinical development of fexinidazole was finalized in late 2022 with the clinical study report for Phase IIIb open-label trial. 1. Continue the work to scale up access to fexinidazole for sleeping sickness caused by the parasite T.b. gambiense.  2. Expand fexinidazole use against the more acute , less common form of the disease caused by T.b. rhodesiense, affecting people in East and Southern Africa. The highly toxic drug melarsoprol is the only treatment currently available for the advanced stage of this form of the disease. 3. Complete development of and then ensure access to acoziborole, an all-new single-dose oral drug that can be given at the point of care, opening the possibility of simplified 'test-and-treat' approaches in primary healthcare settings.  a single-dose oral treatment that holds tremendous promise for efforts to sustainably eliminate the disease.
Dengue In 2022, DNDi established the Dengue Alliance, a truly global partnership of leading public health institutes in endemic countries. Together, DNDi and its partners are working to complement vaccine and vector control strategies by identifying antivirals or host-directed therapies that are effective against Dengue. Together with its partners, DNDi has started preclinical studies and will be starting clinical trials aiming to deliver an affordable and accessible treatment within five years. DNDi is also working together on diagnostics and regulatory and access strategies, as well as jointly raising funds and mobilizing resources. 1. Accelerate innovation for Dengue by delivering an affordable and accessible dengue treatment solution 
2. Complete DNDi's assessment of the dengue burden in Africa, and 
3. identify biomarkers that can accurately predict progression to severe dengue.
Global Antibiotic Research & Development Partnership (GARDP) GARDP’s mission is to develop and deliver new treatments for bacterial infections where drug resistance is present or emerging or for which inadequate treatment exists. 1. GARDP’s antimicrobial exploratory, evaluation and development programme sets out to build a long-term portfolio of therapeutic interventions necessary to address the unavoidable development of resistance to any novel compound brought to patients and recover and share experts´ knowledge to speed up AMR drug discovery.  2. GARDP’s neonatal sepsis programme aims to develop new antibiotic treatments and provide an evidence base for the use of antibiotics, both old and new, in neonates with confirmed or suspected sepsis. 3. GARDP’s paediatric antibiotics programme aims to expedite the development of new, improved and adapted antibiotics to treat serious bacterial infections in children of all ages. The programme aims to develop antibiotics for countries with a high burden of drug-resistance – for use in hospitals and the community – in both LMIC and high-income settings. 4. GARDP’s STI programme aims to develop and register a new, affordable treatment for gonorrhoea, that works on multidrug-resistant cases and will support the integration of a new treatment into current STI management by investigating antibiotic combinations.
Regional offices DNDi is headquartered in Geneva, Switzerland, with eight regional offices worldwide located in Cape Town, Kinshasa, Kuala Lumpur, Nairobi, New Delhi, New York, Rio de Janeiro, and Tokyo. DNDi's regional offices house half our staff and are critical to our patient and partnership-driven model, and essential to DNDi’s strategy, identity, and credibility. They oversee clinical trials, support health ministries and national disease control programmes, provide critical links to patients, clinicians, and researchers; and raise funds to make our activities possible.
COVID-19 and pandemic preparedness Since the start of the COVID-19 pandemic, DNDi has leveraged its experience in public-interest R&D and its alliances with research partners, notably in Africa and Latin America, to contribute to the COVID-19 response and prepare for future pandemics. Since the start of the COVID-19 pandemic, DNDi has coordinated a large COVID-19 clinical trial in 13 African countries, has launched a new pan-African clinical research platform whose objective is to lay the groundwork for clinical trials before outbreaks occur, and is participating in several ambitious drug discovery projects to identify medicine candidates for the treatment of viruses of pandemic potential. 1. ANTICOV is an open-label, randomised, comparative, ‘adaptive platform trial’ that is testing the safety and efficacy of treatments in mild-to-moderate COVID-19 patients. ANTICOV aims to identify early treatments that can prevent progression of COVID-19 to severe disease and potentially limit transmission. 
2. PANTHER  (the PANdemic preparedness plaTform for Health and Emerging infectious Response) aims to contribute to the control of future epidemics or pandemics on the African continent through a flexible ‘ready-to-use’ clinical research platform, supporting preparedness and rapid response through the development and assessment of adapted tools, starting with therapeutics and vaccines in Africa.
3. COVID Moonshot is a non-profit, open-science consortium of scientists from around the world dedicated to the discovery of safe, globally affordable, straight-to-generic, and easily-manufactured antiviral drugs against COVID-19 and future viral pandemics. 
4. AViDD ASAP aims to accelerate the discovery of effective antiviral drugs that can be rapidly advanced into clinical trials and made widely available
5. Nucleoside Booster objective is to identify nucleosides as starting points for the development of novel broad-spectrum antiviral drugs to boost pandemic preparedness.
6. CERCLE (Coalition for Equitable ResearCh in Low-resource sEttings), previously COVID-19 Clinical Research Coalition, aims to advance research driven by the needs of people in low-resource settings around the world.
Chagas disease Together with its partners, DNDi delivered the first formulation of the drug benznidazole for infants and children in 2011, and later piloted a simplified model of care for people with Chagas, promoting test-and-treat approaches in Colombia that are now being replicated elsewhere in Latin America. 1. Improve current treatments in the near-term by developing a safer, shorter treatment using benznidazole. 2. Limit mother to-child transmission and reach people living with Chagas disease with wider roll-out of ‘test-and-treat’ strategies. 3. Identify entirely new drug candidates and initiate the clinical development of at least two compounds, with the aim of launching at least one Phase III trial resulting from this earlier-stage research by 2028.
Hepatitis C virus (HCV) In 2021, DNDi completed development of a simple-to-use, affordable cure for HCV. Ravidasvir, a direct-acting antiviral (DAA), can cure the disease in 12 to 24 weeks when used with sofosbuvir. The first all-oral HCV treatment to be developed through South–South collaboration, ravidasvir acts as both a powerful new therapeutic option, and as a market shaper to bring down the cost of other life-saving HCV drugs in countries where they are priced out of reach. Alongside the development of ravidasvir, DNDi piloted new strategies to link patients to life-saving treatment and care. Through its work with allies in the Hepatitis C Partnership for Control and Treatment (Hepatitis C PACT), these strategies are now being replicated in pilot projects in Asia and Latin America. 1. Continue working with national governments, civil society organizations, and other partners to enable access to affordable DAAs. 2. Foster the political will needed for wide-scale roll-out of test-and-treat strategies. 3. Ensure that key populations facing stigma, discrimination, and other barriers have equitable access to life-saving diagnosis and treatment.
Dynamic Portfolio Unit The Dynamic Portfolio Unit (DPU) is a transversal and multi-dimensional evaluation and decision-making process to allow for rapid and efficient DNDi response to emerging patient needs. The evaluation process for each new opportunity is managed as a project with a transversal project team across all relevant regional offices with leadership from DP Unit to drive the technical, scientific, and access workstreams. The Dynamic Portofolio approach is instrumental for focusing on the most neglected diseases and increasing DNDi’s impact. 1. Identify and evaluate patients’ needs and research and development gaps, through scoping, exploratory evaluation, feasibility assessment for support and integration of potential new diseases for DNDi. 2. Mature ideas co-developed with partners into new projects and services. 3. Implement support models, ranging from “light” approaches (such as knowledge-sharing or helping with an advocacy “push”) to more “active” approaches (such as building new resource platforms or serving as an “incubator” for an idea that may ultimately be externalised or hosted within DNDi).
Mycetoma Treating eumycetoma (fungal mycetoma) is a challenge. The antifungals ketoconazole and itraconazole are currently the only therapies available, but they are expensive, not very effective, and have serious side effects. People with eumycetoma must often undergo multiple amputations, which sometimes result in death. Safe, effective antifungal treatments for eumycetoma that are appropriate for use in rural settings are urgently needed.
DNDi is running the world’s first and only randomized comparative clinical trial for mycetoma, working with its partners on a safe, effective, and affordable treatment. Following advocacy from DNDi and its partners, WHO added mycetoma to the list of NTDs in 2016 – an important step in raising awareness of the disease and encouraging investment in research for diagnostics and treatments that can be easily used in rural areas. 1. Study the efficacy of fosravuconazole to develop a new treatment for mycetoma that can prevent devastating amputation and disability – and ensure access for all people in need. Results presented in 2022 showed that fosravuconazole and itraconazole (the current standard of care) had similar efficacy, with fosravuconazole having practical advantages over itraconazole, including weekly as opposed to twice-daily administration, no need to administer with food, and no contraindication to other drugs. With a favourable safety profile, it showed efficacy even at a low dose. A follow-up study is underway to determine relative rates of long-term disease recurrence. 
2. Use an 'open-source pharma' approach (the Mycetoma Open Source Project (MycetOS)) to discover new treatments targeting Madurella mycetomatis, the most common cause of fungal mycetoma. Participating researchers engage through community-driven, in-kind scientific contributions, with all ideas and results published immediately in real time to an open-access database, free of intellectual property constraints. Leadership of MycetOS project was transitioned from DNDi to University College London in 2022.
Diseases' platforms in endemic regions To consolidate and strengthen existing R&D capacity, promote scientific exchange, and facilitate access to new tools, DNDi works to foster collaborations among key actors in endemic countries, including health ministries, national disease control programmes, regulatory authorities, WHO, academia, and civil society groups, as well as clinicians and health professionals. Initiatives to utilize and strengthen research capacities in low- and middle-income countries and support networks of excellence to sustain public-interest R&D are central to DNDi’s virtual R&D model. They are also critical to realizing our ultimate objective of fostering new innovation ecosystems – driven by scientific leaders in affected countries – that can fundamentally change how R&D in the public interest is realised and delivered. Since 2003, DNDi has supported the creation and maintenance of four regional clinical research platforms: the Chagas Platform, the HAT Platform, the LEAP (Leishmaniasis East Africa Platform), and redeLEISH (Network of Investigators and collaborators in leishmaniasis). 1. Identify and evaluate patients’ needs and R&D gaps. 2. Strengthen and sustain clinical research capacity. 3. Facilitate access to new treatments. 4. Advocate for an enabling policy and regulatory environment for needs-driven R&D.